¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"replacement site"¿¡ ´ëÇÑ ´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
1
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
replacement site
´ëÄ¡ ÀÚ¸®
´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
A-site-P-site moel
AÀÚ¸® PÀÚ¸® ¸ðµ¨
amino acid replacement
¾Æ¹Ì³ë»ê(ß«) ´ëü(ÓÛôð)
conservative amino acid replacement
"º¸Á¸¼º(ÜÁðíàõ) ¾Æ¹Ì³ë»ê ´ëÄ¡(ÓÛöÇ), (ÔÒ) conservative substitution"
enzyme replacement therapy
È¿¼Ò ´ëü Ä¡·á (ý£áÈÓÛôðö½Öû)
isomorphous replacement
µ¿Çü ´ëÄ¡(ÔÒû¡Óßö¹)
radical amino acid replacement
¶óµðÄ® ¾Æ¹Ì³ë»ê ġȯ(öÇüµ)
replacement
´ëÄ¡(ÓÛöÇ)
replacement vector
´ëÄ¡ º¤ÅÍ
acceptor site
¼ö¿ëºÎÀ§ (â¥é»Ý»êÈ)
active site
Ȱ¼º(üÀàõ)ÀÚ¸®
active site-directed irreversible inhibitor
Ȱ¼º(üÀàõ)ÀÚ¸®ÁöÇâÀû ºÒ°¡¿ªÀúÇØÁ¦(ò¦ú¾îÜÝÕʦæ½îÁúªð¥)
alternate-site model
±³´ëºÎÀ§(ÎßÓÛÝ»êÈ)¸ðÅÚ
amino acid attachement site
¾Æ¹Ì³ë»ê(ß«) ºÎÂø(ݾó·)ÀÚ¸®
aminoacyl site
¾Æ¹Ì³ë¾Æ½Ç ÀÚ¸®
aminoacyl-tRNA site
¾Æ¹Ì³ë¾Æ½ÇtRNA ÀÚ¸®
´ÙÀ½
ÅëÇÕ°Ë»ö ¿Ï·á
´ÙÀ½